SCHEDULE: Armistice Capital, Boyd Report 8.72% Stake in VolitionRx

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 8.72% in VolitionRx Ltd., holding 9,380,425 shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 9,380,425 shares of VolitionRx Ltd. Common Stock.
• This ownership represents 8.72% of the class, based on 107,595,421 shares outstanding as of August 7, 2025, as reported in the issuer's 10-Q/A filed on August 15, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities held by the Master Fund.
• Both reporting persons hold shared voting power and shared dispositive power over all 9,380,425 shares.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine beneficial ownership disclosure and does not contain performance or strategic information.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• The disclosure of a significant beneficial ownership stake by Armistice Capital, LLC and Steven Boyd could be viewed positively by shareholders as it indicates a notable institutional investment in VolitionRx Ltd.

Key Dates

Keywords

VolitionRx Ltd, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Investment Adviser, Stake, Common Stock, Equity Holding